Format

Send to

Choose Destination
Cardiovasc Diabetol. 2016 Oct 1;15(1):139.

Current perspectives on cardiovascular outcome trials in diabetes.

Author information

1
Forschergruppe Diabetes e.V., Munich, Ingolstaedter Landstrasse 1, 85764, Neuherberg (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de.
2
Cardiology Unit, Department of Medicine K2, Karolinska Institutet, 171 76, Stockholm, Sweden.
3
Forschergruppe Diabetes e.V., Munich, Ingolstaedter Landstrasse 1, 85764, Neuherberg (Munich), Germany.
4
Institut d'Investigacions Biomèdiques August Pi i Sunyer-IDIBAPS, Mallorca, 183, 08036, Barcelona, Spain.
5
IRCCS MultiMedica, Via Milanese, 300, 20099, Milan, Italy.

Abstract

Cardiovascular disease (CVD) is one of the most common diabetes-associated complications, as well as a leading cause for death in type 2 diabetes patients (T2D). Despite the well-known correlation between the two, up until the 2008 FDA industry guidance for licensing of new anti-hyperglycemic drugs, which required an investigation of cardiovascular outcomes (CVO) of glucose-lowering agents, only a few studies had looked into the relationship between glucose lowering drugs and cardiovascular (CV) risk. Thereafter, CVOT design has focused on non-inferiority short-term studies on high-risk patient populations aiming at capturing CV safety issues. Despite the wealth of information and useful data provided by CVOTs, this approach still suffers from certain limitations. The present review will condense the main results of the most recently completed CVOTs, reflect on the lessons learned, discuss on the issues presented by current CVOT design and offer some suggestions for improvement.

KEYWORDS:

CVOT; Cardiovascular risk; Cardiovascular safety; Diabetes; Non-inferiority

PMID:
27716274
PMCID:
PMC5045635
DOI:
10.1186/s12933-016-0456-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center